Read our new white paper - "Treating the Diabetes Infrastructure"
welcome!
New to Close Concerns?
Subscribe
Already registered?
Log in
WHAT WE DO
consulting
strategic advice and comprehensive information for those interested in the diabetes industry
diabetes close up
our monthly newsletter
industry reports
periodically we take the long view on trends or on specific breakthroughs.
TEAM
disclosure
Close Concerns has ongoing business relationships (in the form of Closer Look subscriptions) with and/or holds stock in the following companies: Abbott, Amylin, Alkermes, Baxter, Bayer, Becton Dickinson, Biocon, Biodel, Boehringer-Ingelheim, Calibra, CeQur, DexCom, Diabetes America, Enject, Eli Lilly, GSK, Insulet, InteKrin, Intuity Medical, J&J, Marcadia, Medtronic, Merck, Novartis, Novo Nordisk, Orexigen, Pfizer, Proteus Biomedical, Roche, sanofi-aventis, Tandem Diabetes, Tolerx, Unomedical, Valeritas, and Vivus. Editorial content for Closer Look, Diabetes Close Up, and diaTribe is independent of these relationships. For any questions on our disclosure, please call +1 415 241 9500 or contact info(at)closeconcerns.com.